• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

    11/12/24 4:00:00 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRNS alert in real time by email
    • ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023
    • Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million
    • Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives
    • Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended
    • Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus
    • Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024.

    "We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "In 2024, our Phase 3 data in status epilepticus and tuberous sclerosis complex showed meaningful clinical activity in certain refractory patients, however, the trials did not meet the thresholds for statistical significance. Given this outcome, we have made the difficult decision to explore strategic alternatives with the goal of maximizing stockholder value while supporting the growth of ZTALMY for patients with CDKL5 deficiency disorder (CDD)."

    Dr. Braunstein continued, "I extend my deepest gratitude to our dedicated employees for their significant contributions to our work, and to the patients and clinicians who participated in our trials. We are proud to have delivered the first-and-only FDA-approved treatment for patients with seizures associated with CDD and hope that our research will serve as a foundation for future innovations in areas of high unmet need."

    ZTALMY® (ganaxolone) Oral Suspension CV

    • Generated net product revenue of $8.5 million for the third quarter of 2024 representing 56% growth versus the third quarter of 2023.
    • Narrowing full year 2024 net product revenue guidance to $33 to $34 million from a range of $33 to $35 million.
    • Announced issuance of new U.S. patent for ZTALMY oral titration regimens covering the treatment of a range of epilepsies, expiring September 2042. 

    Clinical Updates

    • The U.S. Food and Drug Administration (FDA) granted Marinus a Type C meeting, scheduled for the fourth quarter of 2024, to discuss a potential path forward for intravenous (IV) ganaxolone in refractory status epilepticus (RSE).
    • Presented data from the Phase 3 RAISE trial evaluating IV ganaxolone for the treatment of RSE at the Neurocritical Care Society Annual Meeting in October 2024.
    • Announced topline results from the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) whereby the trial did not achieve statistical significance in the primary endpoint.
    • Marinus will continue to support the commercial growth of ZTALMY and activities required by the FDA and European Medicines Agency specific to post-approval commitments related to the CDD indication.

    Ganaxolone development in the RAISE trial has been supported in part by the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50120C00159.

    General Business and Financial Update

    • Marinus has commenced a process to explore strategic alternatives with the goal of maximizing value for its stockholders and has engaged Barclays as an advisor to assist in reviewing its strategic alternatives.
    • Full year 2024 guidance has been narrowed with projected ZTALMY net product revenue between $33 and $34 million and combined selling, general and administrative (SG&A) and research and development (R&D) expenses in the range of approximately $135 to $138 million, including stock-based compensation expense of approximately $20 million.
    • Cost reduction activities were initiated in the fourth quarter of 2024, including suspending further ganaxolone clinical development and a workforce reduction of approximately 45%.
    • Through the execution of the cost reduction plans, the Company had cash and cash equivalents of $42.2 million as of September 30, 2024, to fund the Company's operating expenses and capital expenditure requirements into the second quarter of 2025. 

    Financial Results

    • Recognized $8.5 million and $23.9 million in net product revenue for the three and nine months ended September 30, 2024, respectively, as compared to $5.4 million and $13.0 million for the same periods in the prior year, respectively.
    • Recognized $0.1 million and $0.3 million in Biomedical Advanced Research and Development Authority (BARDA) federal contract revenue for the three and nine months ended September 30, 2024, respectively, as compared to $1.9 million and $10.8 million for the same periods in the prior year, respectively. The decrease was primarily driven by activity associated with the start-up of the API onshoring initiative in the first quarter of 2023 and completion of the BARDA base period funding in the fourth quarter of 2023.
    • R&D expenses were $16.3 million and $61.3 million for the three and nine months ended September 30, 2024, respectively, as compared to $23.7 million and $73.0 million for the same periods in the prior year, respectively. The reduction was due primarily to reduced costs in 2024 associated with the RAISE trial completion and costs associated with start-up of the API onshoring effort in the first quarter of 2023.
    • SG&A expenses were $12.6 million and $47.9 million for the three and nine months ended September 30, 2024, respectively, as compared to $14.9 million and $45.8 million for the same periods in the prior year, respectively. The primary drivers of the decrease for the three month period were decreased personnel and consulting expenses, while the drivers of the increase for the nine month period were increased stock-based compensation expense and commercial expense.
    • The Company had net losses of $24.2 million and $98.7 million for the three and nine months ended September 30, 2024, respectively; cash used in operating activities decreased to $87.8 million for the nine months ended September 30, 2024, compared to $91.0 million for the same period a year ago.
    • At September 30, 2024, the Company had cash and cash equivalents of $42.2 million, compared to cash, cash equivalents and short-term investments of $150.3 million at December 31, 2023.

    Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, to be filed with the Securities and Exchange Commission, which includes further detail on the Company's business plans, operations, financial condition, and results of operations.

    Selected Financial Data (in thousands, except share and per share amounts)

     

    September 30,

    2024

    (unaudited)

     

    December 31,

    2023

    ASSETS

     

     

     

     

     

    Cash and cash equivalents

    $

    42,184

     

    $

    120,572

    Short-term investments

     

    -

     

     

    29,716

    Other assets

     

    21,440

     

     

    20,620

    Total assets

    $

    63,624

     

    $

    170,908

    LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY

     

     

     

     

     

    Current liabilities

    $

    34,504

     

    $

    40,624

    Long term debt, net

     

    41,713

     

     

    61,423

    Revenue interest financing payable, net

     

    36,039

     

     

    33,766

    Other long-term liabilities

     

    18,108

     

     

    18,330

    Total liabilities

     

    130,364

     

     

    154,143

    Total stockholders' (deficit) equity

     

    (66,740)

     

     

    16,765

    Total liabilities and stockholders' (deficit) equity

    $

    63,624

     

    $

    170,908

     

     

    Three Months Ended

    September 30,

     

    Six Months Ended

    September 30,

     

     

    2024

    (Unaudited)

     

    2023

    (Unaudited)

     

    2024

    (Unaudited)

     

    2023

    (Unaudited)

    Revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Product revenue, net

     

    $

    8,468

     

     

    $

    5,429

     

     

    $

    23,928

     

     

    $

    13,010

     

    Federal contract revenue

     

     

    56

     

     

     

    1,891

     

     

     

    295

     

     

     

    10,753

     

    Collaboration revenue

     

     

    17

     

     

     

    18

     

     

     

    53

     

     

     

    36

     

    Total revenue

     

     

    8,541

     

     

     

    7,338

     

     

     

    24,276

     

     

     

    23,799

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    16,334

     

     

     

    23,661

     

     

     

    61,349

     

     

     

    73,006

     

    Selling, general and administrative

     

     

    12,573

     

     

     

    14,868

     

     

     

    47,909

     

     

     

    45,794

     

    Restructuring Costs

     

     

    -

     

     

     

    -

     

     

     

    1,950

     

     

     

    -

     

    Cost of product revenue

     

     

    714

     

     

     

    455

     

     

     

    2,205

     

     

     

    1,047

     

    Total expenses:

     

     

    29,621

     

     

     

    38,984

     

     

     

    113,413

     

     

     

    119,847

     

    Loss from operations

     

     

    (21,080

    )

     

     

    (31,646

    )

     

     

    (89,137

    )

     

     

    (96,048

    )

    Interest income

     

     

    598

     

     

     

    1,895

     

     

     

    3,169

     

     

     

    6,366

     

    Interest expense

     

     

    (3,843

    )

     

     

    (4,242

    )

     

     

    (12,806

    )

     

     

    (12,597

    )

    Other income, net

     

     

    100

     

     

     

    1,021

     

     

     

    52

     

     

     

    1,105

     

    Loss before income taxes

     

     

    (24,225

    )

     

     

    (32,972

    )

     

     

    (98,722

    )

     

     

    (101,174

    )

    Benefit for income taxes

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,538

     

    Net loss applicable to common shareholders

     

    $

    (24,225

    )

     

    $

    (32,972

    )

     

    $

    (98,722

    )

     

    $

    (99,636

    )

    Per share information:

     

     

     

     

     

     

     

     

     

     

     

     

    Net loss per share of common stock—basic and diluted

     

    $

    (0.42

    )

     

    $

    (0.61

    )

     

    $

    (1.73

    )

     

    $

    (1.89

    )

    Basic and diluted weighted average shares outstanding

     

     

    57,229,229

     

     

     

    53,920,109

     

     

     

    57,049,038

     

     

     

    52,755,114

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Other comprehensive loss

     

     

     

     

     

     

     

     

     

     

     

     

    Unrealized gain (loss) on available-for-sale securities

     

     

    -

     

     

     

    43

     

     

     

    20

     

     

     

    (71

    )

    Total comprehensive loss

     

    $

    (24,225

    )

     

    $

    (32,929

    )

     

    $

    (98,702

    )

     

    $

    (99,707

    )

    About Marinus Pharmaceuticals

    Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on LinkedIn, X and Facebook.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, our expectations regarding the review and exploration of strategic alternatives and their potential impact on stockholder value; our expectations regarding the future of the company's operations; our net product revenue and other financial guidance and projections; statements regarding our expected clinical development plans, enrollment in our clinical trials, and regulatory communications, and the timing thereof; our expected cash runway; our expectations and beliefs regarding the FDA and EMA with respect to our product candidates; our expectations regarding our cost reduction plans; the potential safety and efficacy of ganaxolone; and other statements regarding the company's future operations, financial performance, financial position, prospects, objectives and other future event.

    Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk that exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect our operating results, business, or investor perceptions; uncertainties regarding future costs and expenses; Marinus' ability to continue as a going concern; Marinus' ability to maintain compliance with its debt covenants and risks and uncertainties regarding the ability to do; unexpected market acceptance, payor coverage or future prescriptions and revenue generated by ZTALMY; the pricing and reimbursement process can be time consuming and may delay commercialization of ZTALMY in one or more European countries; our dependence on Orion to commercialize ZTALMY in Europe pursuant to the exclusive collaboration agreement; unexpected actions by the FDA or other regulatory agencies with respect to our products; competitive conditions and unexpected adverse events or patient outcomes from being treated with ZTALMY, the company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; our ability to comply with the FDA's requirement for additional post-marketing studies in the required time frames; the size and growth potential of the markets for the company's products, and the company's ability to service those markets; the company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; delays, interruptions or failures in the manufacture and supply of our product; the company's ability to obtain additional funding to support its programs; and the company's ability to protect its intellectual property. This list is not exhaustive and these and other risks are described in our periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241112598483/en/

    Get the next $MRNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRNS

    DatePrice TargetRatingAnalyst
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    8/14/2024Buy → Neutral
    Ladenburg Thalmann
    4/16/2024$20.00 → $2.00Outperform → Neutral
    Robert W. Baird
    4/15/2024$24.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    8/11/2023$14.00 → $9.00Outperform → Perform
    Oppenheimer
    1/20/2023$23.00Outperform
    RBC Capital Mkts
    12/20/2021$32.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $MRNS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

      15-12G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

      2/21/25 8:00:27 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

      SCHEDULE 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      2/14/25 4:00:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

      EFFECT - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

      2/14/25 12:15:08 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. "Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invalu

      5/17/23 4:01:00 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. "With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital

      4/18/23 7:01:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

      9/23/24 7:37:13 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral

      8/14/24 7:42:32 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously

      4/16/24 8:12:28 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:19:58 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:19:21 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:18:26 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

      Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty

      12/30/24 7:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin

      11/12/24 4:00:00 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

      Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as

      10/24/24 8:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:11:48 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Financials

    Live finance-specific insights

    See more
    • Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

      8/13/24 7:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

      7/30/24 8:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/15/24 10:35:20 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

      SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 6:39:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 3:04:48 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care